{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:11:02Z","timestamp":1786565462285,"version":"build-2736575974"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical care, PanBorDex is used primarily in later relapses and is commonly administered in attenuated dosing schedules to mitigate the treatment-related toxicity. We set out to evaluate efficacy and safety outcomes with PanBorDex later in the disease course and evaluate the role of attenuated dosing schedules. This was a retrospective evaluation of patients treated in routine clinical practice between 2016\u20132019 across seven heamatology centres in the UK; patients who received at least one dose of PanBorDex were eligible for inclusion. The dosing schedule of panobinostat (10mg, 15mg or 20mg, twice or three times a week) and bortezomib (0.7mg\/m<jats:sup>2<\/jats:sup>, 1mg\/m<jats:sup>2<\/jats:sup> or 1.3mg\/m<jats:sup>2<\/jats:sup> once or twice weekly) was as per treating physician choice. Patients received treatment until disease progression or unacceptable toxicity. The primary outcome is response rates according to IMWG criteria. Key secondary endpoints include progression-free survival (PFS) and overall survival (OS). Other secondary endpoints include rates of adverse events according to CTCAE criteria. In total, 61 patients were eligible for inclusion and received PanBorDex primarily as \u22655<jats:sup>th<\/jats:sup> line of treatment. One third of patients received PanBorDex at full dose, for the remaining two thirds, treatment was given in reduced dose intensities. The overall response rate was 44.2%, including 14.7% very good partial response (VGPR) rates; 68.8% of patients derived clinical benefit with stable disease or better. The median PFS was 3.4 months; non-refractory patients and those who achieved VGPR benefited from prolonged PFS of 11.4 months and 17.7 months, respectively. The median OS was 9.5 months. The triplet was associated with 45% and 18% incidence of grade 3\u20134 thrombocytopenia and diarrhea, respectively.<\/jats:p>","DOI":"10.1371\/journal.pone.0270854","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T17:31:31Z","timestamp":1657215091000},"page":"e0270854","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-1127","authenticated-orcid":true,"given":"Nadjoua","family":"Maouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvan","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-4796","authenticated-orcid":true,"given":"Supratik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharadha","family":"Sundararaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Collings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Tseu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Ryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-4002","authenticated-orcid":true,"given":"Grant D.","family":"Vallance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"pone.0270854.ref001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"CS Chim","year":"2018","journal-title":"Leukemia"},{"key":"pone.0270854.ref002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"MA Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"pone.0270854.ref003","doi-asserted-by":"crossref","first-page":"100616","DOI":"10.1016\/j.blre.2019.100616","article-title":"Treatment of relapsed multiple myeloma: Evidence-based recommendations","volume":"39","author":"C Durer","year":"2020","journal-title":"Blood Rev"},{"key":"pone.0270854.ref004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3324\/haematol.2016.148882","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"P Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"pone.0270854.ref005","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.blre.2021.100808","article-title":"Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options","author":"K Ramasamy","year":"2021","journal-title":"Blood Rev"},{"key":"pone.0270854.ref006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"K Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"pone.0270854.ref007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"SK Kumar","year":"2012","journal-title":"Leukemia"},{"key":"pone.0270854.ref008","first-page":"1","article-title":"Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice","volume":"2","author":"C Hulin","year":"2019","journal-title":"Heal Sci Reports"},{"key":"pone.0270854.ref009","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"T Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"pone.0270854.ref010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"JF San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"pone.0270854.ref011","first-page":"713","volume":"127","author":"PG Richardson","year":"2018","journal-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment"},{"key":"pone.0270854.ref012","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study","volume":"22","author":"K Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"pone.0270854.ref013","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop C","volume":"117","author":"SV Rajkumar","year":"2011","journal-title":"Blood"},{"key":"pone.0270854.ref014","unstructured":"Health NI of, Institute NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. Available: https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"pone.0270854.ref015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges","volume":"280","author":"P. Atadja","year":"2009","journal-title":"Cancer Lett"},{"key":"pone.0270854.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"P Moreau","year":"2019","journal-title":"Blood Cancer J"},{"key":"pone.0270854.ref017","first-page":"8","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","author":"PG Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"pone.0270854.ref018","first-page":"2331","volume":"122","author":"PG Richardson","year":"2018","journal-title":"CLINICAL TRIALS AND OBSERVATIONS PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma"},{"key":"pone.0270854.ref019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"JJ Keats","year":"2012","journal-title":"Blood"},{"key":"pone.0270854.ref020","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"P Sonneveld","year":"2016","journal-title":"Blood"},{"key":"pone.0270854.ref021","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","article-title":"Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study","volume":"22","author":"JP Laubach","year":"2021","journal-title":"Lancet Oncol"},{"key":"pone.0270854.ref022","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.17076","article-title":"A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients","volume":"191","author":"S Bird","year":"2020","journal-title":"Br J Haematol"},{"key":"pone.0270854.ref023","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"EM Ocio","year":"2010","journal-title":"Haematologica"},{"key":"pone.0270854.ref024","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"UH Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"pone.0270854.ref025","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ajpath.2020.12.016","article-title":"Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma","volume":"191","author":"A Lamanuzzi","year":"2021","journal-title":"Am J Pathol"},{"key":"pone.0270854.ref026","first-page":"66","author":"S Yoon","year":"2017","journal-title":"Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial"},{"key":"pone.0270854.ref027","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"P Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"pone.0270854.ref028","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.03.002","article-title":"An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma","volume":"18","author":"VL Hansen","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"pone.0270854.ref029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clml.2018.05.007","article-title":"Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat","volume":"18","author":"JD Cavenagh","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"pone.0270854.ref030","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"A Palumbo","year":"2015","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T17:32:18Z","timestamp":1657215138000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270854"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Solimando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0270854","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}